On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) was 5.39% up from the session before settling in for the closing price of $1.67. A 52-week range for AKBA has been $1.52 – $4.08.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 32.58%. When this article was written, the company’s average yearly earnings per share was at 109.09%. With a float of $256.75 million, this company’s outstanding shares have now reached $265.23 million.
Akebia Therapeutics Inc (AKBA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akebia Therapeutics Inc stocks. The insider ownership of Akebia Therapeutics Inc is 3.25%, while institutional ownership is 47.37%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.1 earnings per share (EPS) during the time that was less than consensus figure (set at -0.08) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.03 per share during the current fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
You can see what Akebia Therapeutics Inc (AKBA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.08. Likewise, its price to free cash flow for the trailing twelve months is 14.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.18 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Compared to the last year’s volume of 4.22 million, its volume of 6.65 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 26.85%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 7.57%, which indicates a significant decrease from 19.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1639 in the past 14 days, which was higher than the 0.1498 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.6266, while its 200-day Moving Average is $2.7491. Nevertheless, the first resistance level for the watch stands at $1.8400 in the near term. At $1.9200, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0050. If the price goes on to break the first support level at $1.6750, it is likely to go to the next support level at $1.5900. Should the price break the second support level, the third support level stands at $1.5100.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are 265,366K outstanding shares of the company, which has a market capitalization of 467.04 million. As of now, sales total 160,180 K while income totals -69,410 K. Its latest quarter income was 62,470 K while its last quarter net income were 250 K.
